Vivus Sells Erectile Treatment for $23.5M
Vivus (NASDAQ: VVUS), the Mountain View, CA-based developer of an obesity drug, said today it has sold its marketed treatment for erectile dysfunction. Lakewood, NJ-based Meda agreed to pay $23.5 million for the assets related to transurethral alprostadil (Muse). Meda has been business partners with Vivus in Europe since 2000, Vivus said. Selling the Muse assets will allow Vivus to focus on commercializing the obesity drug (Qnexa) that it is seeking to market in the U.S.